Sulfur Containing Hetero Ring Patents (Class 548/527)
-
Publication number: 20090318449Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein J1, J2, B, Y, and A are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: May 13, 2009Publication date: December 24, 2009Applicant: ALLERGAN, INC.Inventors: David W. Old, Robert M. Burk
-
Publication number: 20090286992Abstract: An iodonium compound of formula (I): where RAR1 is a C5-6 aryl group, bearing at least one substituent selected from formyl, thionoacyl, acylamidocarboxy, thionoester, azo, C2-20 alkenyl, C2-20 alkynyl, and (CH2)nRC, where RC is selected from ether, amino, azo and thioether; RAR2 is a C5-10 aryl group, optionally substituted by one or more groups selected from C1-12 alkyl, C5-12 aryl, C3-12 heterocyclyl, ether, thioether, nitro, cyano and halo, and may be linked to a solid support or fluorous tag; and X is a counteranion.Type: ApplicationFiled: May 15, 2009Publication date: November 19, 2009Inventors: Michael Andrew Carroll, Ran Yan
-
Publication number: 20090286787Abstract: A compound comprising or a pharmaceutically acceptable salt thereof, or a prodrug thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.Type: ApplicationFiled: April 22, 2009Publication date: November 19, 2009Applicant: ALLERGAN, INC.Inventors: David W. Old, Danny T. Dinh
-
Patent number: 7612068Abstract: The present invention relates to compounds of formula I wherein the substituents are as defined below. The compounds of formula I are useful for the treatment of diseases such as schizophrenia, including both the positive and the negative symptoms of schizophrenia and other psychoses.Type: GrantFiled: April 27, 2004Date of Patent: November 3, 2009Assignee: H. Lundbeck A/SInventors: Garrick P. Smith, Gitte K. Mikkelsen, Kim Andersen, Daniel R. Greve, Jorgen Eskildsen
-
Patent number: 7608592Abstract: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: GrantFiled: June 28, 2006Date of Patent: October 27, 2009Assignee: ViroBay, Inc.Inventors: Michael Graupe, John O. Link, Chandrasekar Venkataramani
-
Patent number: 7601752Abstract: The invention is concerned with novel pyrrolidine derivatives of formula (I) wherein X, Y, R1, R2 and R3 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.Type: GrantFiled: November 6, 2006Date of Patent: October 13, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Lilli Anselm, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Jacques Himber, Bernd Kuhn, Narendra Panday, Fabienne Ricklin, Stefan Thomi
-
Publication number: 20090239867Abstract: Disclosed herein is a compound comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, X, R and D are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: March 17, 2009Publication date: September 24, 2009Applicant: ALLERGAN, INC.Inventor: David W. Old
-
Publication number: 20090239866Abstract: Novel PDF inhibitors and novel methods for their use are provided.Type: ApplicationFiled: July 28, 2006Publication date: September 24, 2009Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Jeffrey Michael Axten, Jesus R. Medina
-
Patent number: 7592364Abstract: Therapeutic compounds, compositions, medicaments, and methods are disclosed herein.Type: GrantFiled: February 7, 2007Date of Patent: September 22, 2009Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20090233980Abstract: A compound comprising or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.Type: ApplicationFiled: November 25, 2008Publication date: September 17, 2009Inventors: David W. Old, Danny T. Dinh
-
Patent number: 7589213Abstract: Therapeutic compounds, compositions, medicaments, and methods are disclosed herein.Type: GrantFiled: March 17, 2008Date of Patent: September 15, 2009Inventor: David W. Old
-
Publication number: 20090227635Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, B, and J are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: February 27, 2009Publication date: September 10, 2009Applicant: ALLERGAN, INC.Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20090227653Abstract: A compound comprising or a pharmaceutically acceptable salt thereof, or a prodrug thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.Type: ApplicationFiled: May 15, 2009Publication date: September 10, 2009Applicant: ALLERGAN, INC.Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20090227636Abstract: Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: May 14, 2009Publication date: September 10, 2009Applicant: ALLERGAN, INC.Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20090215847Abstract: There is provided compounds of formula I, wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.Type: ApplicationFiled: April 12, 2006Publication date: August 27, 2009Inventors: Mathias Alterman, Anders Hallberg, Xiongyu Wu
-
Patent number: 7579340Abstract: The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.Type: GrantFiled: August 22, 2007Date of Patent: August 25, 2009Assignee: Pfizer IncInventors: Ronald Biediger, Jie Chen, Daxin Gao, Robert Market, Chengde Wu
-
Patent number: 7569598Abstract: The present invention relates to a process for the enrichment of the R,R- or S,S-configured glycopyrronium isomers and their thienyl derivatives having the R,S or S,R configuration.Type: GrantFiled: December 18, 2003Date of Patent: August 4, 2009Assignee: Meda Pharma GmbH & Co. KGInventors: Christian Noe, Martin Walter
-
Patent number: 7569704Abstract: The present invention relates to a novel dye compound, represented by the following formula (I): wherein R1, D1, D2, X, and Y are defined the same as the specification. The dye compound of the present invention is suitable for Dye-Sensitized Solar Cell (DSSC). In addition, the dye compound of the present invention has high molar absorption coefficient, so that the DSSC manufactured by the dye compound of the present invention can have good photoelectric characteristics.Type: GrantFiled: May 29, 2008Date of Patent: August 4, 2009Assignees: Everlight USA, Inc., Academia SinicaInventors: Jiann-T'suen Lin, Yung-Sheng Yen, Ying-Chan Hsu, Ta-Chung Yin
-
Publication number: 20090192159Abstract: Disclosed herein is a compound represented by the formula: Methods, compositions, and medicaments related to these compounds are also disclosed.Type: ApplicationFiled: January 16, 2009Publication date: July 30, 2009Inventor: David W. Old
-
Patent number: 7553798Abstract: Compounds of the formula (I), in which the substituents are as defined in claim 1 are suitable for use as microbiocides.Type: GrantFiled: June 21, 2005Date of Patent: June 30, 2009Assignee: Syngenta Crop Protection, Inc.Inventors: Clemens Lamberth, Camilla Corsi, Josef Ehrenfreund, Hans Tobler, Harald Walter
-
Publication number: 20090163497Abstract: The present invention provides compounds of general formula (I) or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.Type: ApplicationFiled: October 26, 2006Publication date: June 25, 2009Inventors: Amy M. Elder, Shomir Ghosh, Sian Griffiths, Prakash Raman, Francois Soucy, Kevin Sprott, Qing Ye
-
Patent number: 7550502Abstract: A compound comprising or a pharmaceutically acceptable salt thereof, or a prodrug thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.Type: GrantFiled: March 20, 2007Date of Patent: June 23, 2009Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Patent number: 7550448Abstract: Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: May 11, 2007Date of Patent: June 23, 2009Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Patent number: 7547685Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof are disclosed herein. Details are provided herein. Compositions, methods, and medicaments related thereto are also disclosed.Type: GrantFiled: November 7, 2005Date of Patent: June 16, 2009Assignee: Allergan, Inc.Inventor: David W. Old
-
Publication number: 20090137789Abstract: Fluorescent oligonucleotide probe having a general formula (I), wherein Onu represents an oligonucleotide residue, Thion represents a fluorescent oligothiophene containing n thiophenic rings, n being an integer lower than 8, L representing a binder conceived to maintain Thion mobile in relation to Onu in a manner so that Thion can perform its fluorescent action correctly, and Onu can perform its hybridization action. (I)=Onu-L-Thion.Type: ApplicationFiled: November 10, 2005Publication date: May 28, 2009Inventors: Giovanna Barbarella, Massimo Luigi Capobianco, Giovanna Sotgiu, Massimo Zambianchi, Fabio Aruffo, Mario Benzi, Marina Naldi, Umberto Negri
-
Publication number: 20090131659Abstract: The present invention provides compounds useful for prevention, treatment or alleviation of diseases against which activation of the thrombopoietin receptor is effective. A compound represented by the formula (1): wherein A, B, R1, L1, R2, L2, L3, Y, L4, R3 and X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.Type: ApplicationFiled: December 14, 2005Publication date: May 21, 2009Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Katsuaki Miyaji, Shunsuke Iwamoto, Satoshi Nakano, Hirofumi Ota, Yukihiro Shigeta, Yutaka Hirokawa, Kazufumi Yanagihara, Koji Toyama, Shingo Owada, Masato Horikawa, Norihisa Ishiwata
-
Publication number: 20090123514Abstract: Conductive surfaces of e.g., implantable devices, coated with electropolymerized polymers having active substances attached thereto are disclosed. Electropolymerizable monomers designed and used for obtaining such conductive surfaces and processes, devices and methods for attaching the electropolymerized polymers to conductive surfaces are also disclosed. The polymers, processes and devices presented herein can be beneficially used in the preparation of implantable medical devices.Type: ApplicationFiled: July 19, 2006Publication date: May 14, 2009Applicant: Elutex Ltd.Inventor: Abraham J. Domb
-
Publication number: 20090118500Abstract: A compound represented by the formula (I) (wherein R1, R2, R3 and R4 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.Type: ApplicationFiled: July 13, 2006Publication date: May 7, 2009Applicant: NISSAN CHEMICAL INDUSTRIES, LTDInventors: Katsuaki Miyaji, Kazufumi Yanagihara, Yukihiro Shigeta, Shunsuke Iwamoto, Masato Horikawa, Yutaka Hirokawa, Shingo Owada, Satoshi Nakano, Hirofumi Ota, Norihisa Ishiwata
-
Publication number: 20090099249Abstract: Disclosed herein is a compound having a structure Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: December 15, 2008Publication date: April 16, 2009Inventors: David W. Old, Robert M. Burk
-
Publication number: 20090093452Abstract: Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein RQ, R7, n, Q2, Q3, Y, and X1-X3 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.Type: ApplicationFiled: August 24, 2007Publication date: April 9, 2009Inventors: Kenneth He Huang, Steven E. Hall, James Veal
-
Patent number: 7504520Abstract: The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.Type: GrantFiled: May 10, 2006Date of Patent: March 17, 2009Assignee: Abbott LaboratoriesInventors: Arthur Gomtsyan, Richard J. Perner, John R. Koenig, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Chih-Hung Lee
-
Patent number: 7501451Abstract: Mono-acylated o-phenylendiamines derivatives of formula A: which are useful for the treatment of diseases mediated by the inhibition of histone deacetylase, such as cancer.Type: GrantFiled: December 6, 2005Date of Patent: March 10, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Georg Fertig, Frank Herting, Manfred Kubbies, Anja Limberg, Ulrike Reiff, Michael Weidner
-
Publication number: 20090062284Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl acetamides of Formula (I): wherein Ar, Y, R1, R2, R4, R5, q and x are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder; Parkinson's disease; Alzheimer's disease; attention deficit disorder; attention deficit hyperactivity disorder; depression; or fatigue associated with a neurological disease; as well as the promotion of wakefulness.Type: ApplicationFiled: August 27, 2008Publication date: March 5, 2009Applicant: Cephalon, Inc.Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, Marie-Edith Gourdel, Greg A. Hostetler, Mohamed Iqbal, Brigitte Lesur, Philippe Louvet, Eric Riguet, Dominique Schweizer, Christophe Yue
-
Publication number: 20090054396Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.Type: ApplicationFiled: September 8, 2008Publication date: February 26, 2009Applicant: ASTRAZENECA ABInventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Mei Su, Dingwei Yu, Stephanie Springer
-
Publication number: 20090041721Abstract: The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.Type: ApplicationFiled: August 9, 2007Publication date: February 12, 2009Inventors: Deqiang Niu, Yonghua Gai, Yat Sun Or, Zhe Wang
-
Publication number: 20090036421Abstract: [Problem] To provide a compound which may be used for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS). [Means for Resolution] It was found that a pyrrole derivative characterized by the possession of a guanidinocarbonyl group or amido group as a substituent group at the 3-position, or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).Type: ApplicationFiled: February 19, 2007Publication date: February 5, 2009Applicant: ASTELLAS PHARMA INCInventors: Ryushi Seo, Hidetaka Kaku, Hiroyoshi Yamada, Daisuke Kaga, Shinobu Akuzawa
-
Publication number: 20090036436Abstract: Compounds of Formulas 1 and 2 where the variables have the meaning disclosed in the specification, have analgesic and in some cases immunostimulant activity.Type: ApplicationFiled: January 25, 2006Publication date: February 5, 2009Inventors: Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E. Donello
-
Patent number: 7482374Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.Type: GrantFiled: July 17, 2004Date of Patent: January 27, 2009Assignee: Glaxo Group LimitedInventors: Alan David Borthwick, Henry Anderson Kelly, Nigel Stephen Watson, Robert John Young
-
Patent number: 7479504Abstract: The present invention encompasses compounds of Formula 1: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.Type: GrantFiled: January 15, 2003Date of Patent: January 20, 2009Assignee: Merck & Co., Inc.Inventors: Robert L. Bugianesi, George A. Doherty, Amy Gentry, Jeffrey J. Hale, Christopher L. Lynch, Sander G. Mills, William E. Neway, III
-
Patent number: 7476663Abstract: The present invention relates to new substituted thiophene-2-carboxylic acid amides of general formula wherein A, and R1 to R8c are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.Type: GrantFiled: May 10, 2005Date of Patent: January 13, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Roland Pfau, Henning Priepke, Kai Gerlach, Wolfgang Wienen, Annette Schuler-Metz, Herbert Nar, Sandra Handschuh
-
Publication number: 20090012127Abstract: Compounds of Formula (I) wherein E, A and R1 are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.Type: ApplicationFiled: June 26, 2006Publication date: January 8, 2009Applicant: ASTRAZENECA ABInventors: Thomas R. Simpson, Michael Balestra, Dean G. Brown, Cathy L. Dantzman, Glen E. Ernst, William Frietze, Christopher R. Holmquist, James Kang, Frances M. McLaren, Reed W. Smith, JR., James M. Woods
-
Patent number: 7473702Abstract: A compound comprising or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.Type: GrantFiled: May 24, 2007Date of Patent: January 6, 2009Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20080292587Abstract: The present invention discloses compounds of formulae I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: April 24, 2008Publication date: November 27, 2008Inventors: Ying Sun, Yat Sun Or, Zhe Wang
-
Publication number: 20080287687Abstract: The present invention relates to a production method of a compound represented by the formula (3), which includes reacting a compound represented by the formula (2) with a diphenylmethyl halide compound represented by the formula (1) in the presence of alkali metal alkoxide. According to the method of the present invention, compound (3) can be produced at a high purity and in a high yield. wherein each symbol is as defined in the specification, *1 and *2 each show an asymmetric carbon atom, and the configuration of the asymmetric carbon atom of *1 and *2 is (S,S) or (R,R).Type: ApplicationFiled: October 31, 2007Publication date: November 20, 2008Applicant: AJINOMOTO CO. INCInventors: Takayuki Hamada, Kunisuke Izawa, Vadim A. Soloshonok
-
Patent number: 7449481Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl acetamides of Formula (I): wherein Ar, Y, R1, R2, R4, R5, q and x are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder; Parkinson's disease; Alzheimer's disease; attention deficit disorder; attention deficit hyperactivity disorder; depression; or fatigue associated with a neurological disease; as well as the promotion of wakefulness.Type: GrantFiled: April 12, 2005Date of Patent: November 11, 2008Assignee: Cephalon, Inc.Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, Marie-Edith Gourdel, Greg Hostetler, Mohamed Iqbal, Brigitte Lesur, Philippe Louvet, Eric Riguet, Dominique Schweizer, Christophe Yue
-
Publication number: 20080274082Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: April 24, 2008Publication date: November 6, 2008Inventors: Yonghua Gai, Ying Sun, Yat Sun Or, Zhe Wang
-
Publication number: 20080269498Abstract: Therapeutic compounds, compositions, medicaments, and methods are disclosed herein.Type: ApplicationFiled: March 17, 2008Publication date: October 30, 2008Inventor: David W. Old
-
Publication number: 20080262073Abstract: The invention describes new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases.Type: ApplicationFiled: December 27, 2005Publication date: October 23, 2008Inventors: Fernando Pedro Cossio Mora, Manel Esteller Badosa, Aizpea Zubia Olascoaga, Dorleta Otaegui Ansa
-
Publication number: 20080255220Abstract: Disclosed herein is a compound comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, X, R and D are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: June 6, 2006Publication date: October 16, 2008Applicant: ALLERGAN, INC.Inventor: David W. Old
-
Patent number: 7423061Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.Type: GrantFiled: August 12, 2004Date of Patent: September 9, 2008Assignee: AstraZeneca ABInventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Stephanie Springer, Mei Su, Dingwei Yu